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autologous dendritic cell (DC) vaccine.
Methods: There were 25 patients with MDRnXDR pulmonary TB included in the study. DCs
were obtained both from peripheral blood monocytes and bone marrow isolated stem cells
using standard protocols. DCs were primed with either autologous M. tuberculosis lysates
or CFP-10 peptides and cultured with maturation inducers. DCs were tested for immuno-
phenotype, viability and sterility and injected into the patients subcutaneously three times
at 2- to 3-week intervals. Clinical monitoring, sputum assessments, chest X-rays and
immune status were performed before and 2–3 months after the treatment. The control
group (C) consisted of 25 patients with MDRnXDR TB matched by sex and age.
Results: DCs obtained from all patients were sterile, viable, morphologically intact and phe-
notypically mature (expression of CD83 and CD86 being >80%). The number of injected DCs
averaged 10.2 (range: 8.3–15.6) · 106.
Treatment of TB patients with autologous DCs was safe and well tolerated. No significant
side effects which required medical aid were noted during the study.
The combination of standard treatment and DC-vaccination promoted the decrease or
complete clearance of mycobacteria tuberculosis from the sputum (DC-treated patients –
69.23 ± 12.8% versus 30.76 ± 12.8% in C, p < 0.05) and X-ray improvement (69.23 ± 12.8% ver-
sus 30.76 ± 12.8% in C, p < 0.05).
Treatment with DCs was also associated with the significant increase of antigen-specific T-
cells in the blood, which reflects the accumulation of antigen-specific T-cells in peripheral
blood and indicates the restoration of immune response against mycobacteria tuberculosis.
Conclusions: DC-based treatment may become an effective valuable method of cellular
immunotherapy for MDR- and XDR-TB patients.
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